ArticleCancer research communications2025
Tumor Cell Plasticity and Stromal Microenvironment Distinguish Papillary and Follicular Growth Patterns in a Mouse Model of BRAFV600E-Induced Thyroid Cancer.
Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Integrative proteomics and metabolomics advance early cancer detection and targeted therapy with emerging technologies and clinical applications.Discover oncology · 2026Review
- Prognostic impact of RAS mutation on papillary thyroid carcinoma: a systematic review and meta-analysis.Thyroid research · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractDifferentiated thyroid cancer primarily classified by tumor histology comprises follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma (PTC), which represent distinct malignancies regarding the pattern of tumor spreading, responsiveness to radioiodine treatment, and clinical outcome. As FTC and PTC also differ genetically i.e., RAS mutations predominate in FTC whereas mutant BRAF is much more frequent in PTC, it is assumed although yet unproven that the archetypical tumor growth pattern – follicular versus papillary – depends on mutation identity and potentially the graded signaling output of the MAPK pathway that differs in response to constitutive activation by RAS or BRAF. In this study, we show by clonal tracing in mice carrying a Braf mutant allele with targeted expression of BRAFV600E exclusively in the thyroid gland that sporadically developed tumors either adopt a follicular or a papillary phenotype depending on follicle origin. Moreover, a single tumor clone may transit from papillary to follicular growth associated with asymmetric distribution of stromal tissue in the immediate vicinity of the tumor. Key to these observations is monitoring the progeny of cells undergoing spontaneous recombination of both BrafCA and the reporter gene because of Cre leakage which, in contrast to after induced oncogene activation comprising all target cells, implies that tumors develop stochastically and asynchronously originating from a limited number of BRAF mutant cells and taking place within a preserved thyroid tissue microenvironment. The results suggest that the natural heterogeneity of follicles and tumor cell plasticity modify BRAFV600E-induced neoplastic growth leading to divergent tumor histogenesis. SIGNIFICANCE: Cell-of-origin intrinsic features rather than driver mutation identity influence tumor growth patterning in differentiated thyroid cancer and might impact histopathologic diagnosis of thyroid carcinoma subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.